CS
DNLI icon

Comerica Securities’s Denali Therapeutics DNLI Stock Holding History

Comerica Securities’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-225
Closed -$6.26K – 714
2022
Q4 		$6.26K Buy
+225
New +$6.7K ﹤0.01% 1091

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Comerica Securities's DNLI Position: Q1 2023 in Review

Comerica Securities sold out of Denali Therapeutics (DNLI) in Q1 2023, closing a stake of 225 shares — an estimated $6.26K sold.

Comerica Securities first reported a position in DNLI in Q4 2022 and held it in 1 quarter. The position peaked at $6.26K in Q4 2022. 202 funds tracked by Wall St. Rank hold DNLI as of Q1 2023.

  • Comerica Securities reported no remaining Denali Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Comerica Securities sold 225 Denali Therapeutics shares in Q1 2023, an estimated $6.26K.
  • Comerica Securities first reported a position in Denali Therapeutics in Q4 2022 and held it in 1 quarter.
  • Comerica Securities's Denali Therapeutics position peaked at $6.26K in Q4 2022.
  • 202 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.